FibroGen
Festus Ariche has over four decades of experience in facilities and lab operations within the biotechnology and pharmaceutical industries. Currently serving as Senior Manager of Facilities and Lab Operations at FibroGen, Inc. since April 1999, Festus has previously held the position of Manager of Lab Operations at Geron Corp from 1992 to 1999, as well as Manager of Lab Operations at Genentech from 1980 to 1999. This extensive background highlights Festus' expertise in managing complex laboratory environments.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.